Welcome to LookChem.com Sign In|Join Free

CAS

  • or

58-63-9

Post Buying Request

58-63-9 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

58-63-9 Usage

Chemical Properties

White crystalline powder

Originator

Foreart,Guarnieri,Italy,1970

Occurrence

Inosine is a synthetic

Uses

Different sources of media describe the Uses of 58-63-9 differently. You can refer to the following data:
1. Has neuroprotective properties improving axonal wiring. Has been used to treat stroke patients to restore neural function.
2. cell function activator, cardiotonic
3. Suppresses the increase of glucose and insulin in the blood
4. Inosine has been used:as a medium supplement in nucleotide rescue experiments in pancreatic cancer cell lines.as a component in holidic (synthetic) medium and in larval two-choice preference assay.as a reference standard in mass spectroscopy.

Definition

ChEBI: A purine nucleoside in which hypoxanthine is attached to ribofuranose via a beta-N9-glycosidic bond.

Manufacturing Process

As described in US Patent 3,049,536, inosine may be prepared starting with adenosine.The Deamination of Adenosine: 20 g of adenosine are dissolved in one liter of water by warming, and after cooling to room temperature 120 g of barium nitrite (monohydrate) are added to the solution. Under stirring there is added in time intervals of one hour 160 cc of 2 N sulfuric acid after each time interval. After the third addition, the reaction mass is allowed to stand for 3 hours at room temperature. The solution is then tested for barium, and if some barium is still present a slight excess of sulfuric acid is added. 300 cc of methanol is then added. In order to drive off the excess of nitrous acid, CO2 is conducted through the solution until the solution is free of nitrous acid as determined by testing with potassium iodide-starch paper. The precipitated barium sulfate is separated by centrifugation. The residue is washed one time with about 500 cc of water. The total volume of the centrifugate is about 2.3 liters.Isolation of Inosine by Ion Exchange Method: Half of the above clear centrifugate (1.15 liters) is treated with 250 cc of anion exchange (bicarbonate form) and stirred together therewith for 16 hours at room temperature. The pH value is increased thereby to about 4 to 5. The ion exchanger is filtered off under suction and washed 3 times, each time with 150 cc of water. The solution is brought to a pH value of 7 by means of normal sodium hydroxide (total volume of the solution about 1.55 liters), and concentrated to a volume of about 100 cc under vacuum.The inosine is crystallized overnight in an ice box and the inosine is then filtered off by suction, washed with a small amount of ice water and dried at a temperature of 105°C. A first fraction of crude inosine consisting of 5.4 g having a purity of 99% is obtained. Further fractions of crude inosine are obtained from the mother liquid by concentration, the total amount constituting 3.2 g having a purity of 96 to 98%. The yield of crude inosine is 8.6 g which is equal to 86%.Recrystallization of the Crude Inosine: 17.0 g of crude inosine are dissolved in 400 cc of 80% ethanol in a water bath, filtered while hot and brought to crystallization in an ice box. After standing overnight the crystalline material is filtered off under suction and washed with ice water. The pure inosine is dried in a drying chamber at a temperature of 105°C. The yield of pure inosine is 15.0 g which is equal to 75%. The yield can be further increased by workingup the mother liquor of the crystallization as set forth above.Alternatively, inosine may be made by fermentation as described in US Patent 3,111,459. 3 ml portions of a culture medium consisting of glucose (5 g/dl), ammonium chloride (0.4 g/dl), urea (0.4 g/dl), KH2PO4 (0.1 g/dl), MgSO4 · 7H2O (0.02 g/dl), Mn++ (2 ppm), Fe++ (2ppm), casein hydrolyzate (0.2 g/dl), yeast extract (0.2 g/dl), corn steep liquor (0.2 ml/dl), polypeptone (0.1 g/dl), meat extract (0.1 g/dl) and sodium ribonucleate (10 mg/dl) were poured into respective test tubes and each tube was sterilized at 115°C for 10 minutes. Thereafter separately sterilized calcium carbonate was added in the amount of 2 g/dl and then cells of Bacillus subtilis S26910 were inoculated into the above media and cultured with shaking at 30°C for 20 hours.The resulting culture liquids were utilized for seeding, 20 ml of the medium having the composition described above were poured into a 500 ml shaking flask and sterilized at 115°C for 10 minutes and five drops of the above seed were added, and then cultured with shaking at 30°C for 65 hours. Thereafter 0.15 g/dl of inosine were accumulated.The inosine-containing solution, which was obtained by separating the cells from the resulting fermentation liquid, was treated with both decolorizing resins and anion exchange resins by means of a conventional method and then acetone was added to crystallize the inosine. 1.47 g of the crude crystals of inosine were obtained from 3.5 liters of the culture liquid containing 1 g of inosine per liter.

Therapeutic Function

Cardiotonic

General Description

Inosine is a non-canonical nucleotide majorly present as monophosphate. It has ability to base pair with deoxythymidine, deoxyadenosine and deoxyguanosine. Incorporation of inosine in place of guanine modulates translational events. Inosine has antioxidant, anti-inflammatory and neuroprotective functionality. Inosine is prescribed as a therapeutic supplement for nerve injury, inflammation and oxidative stress. It modulates biological processes through adenosine receptors. Its enhances neurite outgrowth in depressive disorders via adenosine receptors. Inosine is also used for treating sepsis in infections.

Biochem/physiol Actions

Inosine is a potent stimulator of nerve growth factor (NGF) induced neurite outgrowth. The elevated levels of inosine in brain following injury are associated with the increased expression proteins related to axonal regeneration and growth. Mice given inosine demonstrated enhanced recovery of fine motor control following ischemic brain damage. Inosine may be used in studies of the process A-to-I RNA editing.

Purification Methods

(-)-Inosine forms anhydrous crystals from aqueous 80% EtOH but the dihydrate from H2O. [Beilstein 31 H 25, 26 III/IV 2087.]

Check Digit Verification of cas no

The CAS Registry Mumber 58-63-9 includes 5 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 2 digits, 5 and 8 respectively; the second part has 2 digits, 6 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 58-63:
(4*5)+(3*8)+(2*6)+(1*3)=59
59 % 10 = 9
So 58-63-9 is a valid CAS Registry Number.
InChI:InChI=1/C10H12N4O5/c15-1-4-6(16)7(17)10(19-4)14-3-13-5-8(14)11-2-12-9(5)18/h2-4,6-7,10,15-17H,1H2,(H,11,12,18)/t4-,6-,7-,10?/m1/s1

58-63-9 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • TCI America

  • (I0037)  Inosine  >98.0%(HPLC)(T)

  • 58-63-9

  • 25g

  • 530.00CNY

  • Detail
  • TCI America

  • (I0037)  Inosine  >98.0%(HPLC)(T)

  • 58-63-9

  • 500g

  • 4,500.00CNY

  • Detail
  • Alfa Aesar

  • (A14459)  Inosine, 98+%   

  • 58-63-9

  • 5g

  • 219.0CNY

  • Detail
  • Alfa Aesar

  • (A14459)  Inosine, 98+%   

  • 58-63-9

  • 25g

  • 628.0CNY

  • Detail
  • Alfa Aesar

  • (A14459)  Inosine, 98+%   

  • 58-63-9

  • 100g

  • 2025.0CNY

  • Detail

58-63-9SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name Inosine

1.2 Other means of identification

Product number -
Other names 6-Oxopurine riboside

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:58-63-9 SDS

58-63-9Synthetic route

Acetic acid (2R,3R,4R,5R)-4-acetoxy-2-[bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-5-(6-hydroxy-purin-9-yl)-tetrahydro-furan-3-yl ester

Acetic acid (2R,3R,4R,5R)-4-acetoxy-2-[bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-5-(6-hydroxy-purin-9-yl)-tetrahydro-furan-3-yl ester

A

inosine
58-63-9

inosine

B

adenosine
58-61-7

adenosine

Conditions
ConditionsYield
Multistep reaction;
adenosine
58-61-7

adenosine

inosine
58-63-9

inosine

Conditions
ConditionsYield
With sodium phosphate buffer; adenosine deaminase In water at 27℃; pH=7.5; Enzyme kinetics;
With adenosine deaminase Kinetics; Concentration; Enzymatic reaction;
Multi-step reaction with 2 steps
1: purine nucleoside phosphorylase from aeromonas hydrophila II / aq. phosphate buffer / 20 °C / pH 7.5 / Enzymatic reaction
2: aq. phosphate buffer / 20 °C / pH 7.5
View Scheme
With adenine deaminase from E. coli; water In aq. phosphate buffer at 25℃; pH=7.0; Catalytic behavior; Reagent/catalyst; Enzymatic reaction;
Conditions
ConditionsYield
With recombinant nucleoside acid phosphatase/phosphotransferase from Escherichia blattae at 30℃; for 0.166667h; pH=5; Kinetics; Time; pH-value; Temperature; Reagent/catalyst; aq. acetate buffer;
uridine
58-96-8

uridine

inosine
58-63-9

inosine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1.1: potassium phosphate; recombinant Escherichia coli uridine phosphorylase / water / 72 h / 50 °C / pH 7 / Enzymatic reaction
1.2: 24 h / 4 °C
2.1: recombinant Escherichia coli purine nucleoside phosphorylase / 20 °C / pH 7 / Enzymatic reaction
View Scheme
Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: purine nucleoside phosphorylase from aeromonas hydrophila II / aq. phosphate buffer / 20 °C / pH 7.5 / Enzymatic reaction
2: aq. phosphate buffer / 20 °C / pH 7.5
View Scheme
α-D-ribose-1-phosphate
99790-49-5

α-D-ribose-1-phosphate

inosine
58-63-9

inosine

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: aq. phosphate buffer / 20 °C / pH 7.5
2: purine nucleoside phosphorylase from aeromonas hydrophila II / aq. phosphate buffer / 20 °C / pH 7.5 / Enzymatic reaction
3: aq. phosphate buffer / 20 °C / pH 7.5
View Scheme
Multi-step reaction with 3 steps
1: aq. phosphate buffer / 20 °C / pH 7.5
2: purine nucleoside phosphorylase from aeromonas hydrophila II / aq. phosphate buffer / 20 °C / pH 7.5 / Enzymatic reaction
3: aq. phosphate buffer / 20 °C / pH 7.5
View Scheme
α-D-ribose-1-phosphate
99790-49-5

α-D-ribose-1-phosphate

inosine
58-63-9

inosine

Conditions
ConditionsYield
In aq. phosphate buffer at 20℃; pH=7.5;
α-D-ribofuranose-1-O-phosphate barium salt

α-D-ribofuranose-1-O-phosphate barium salt

6-hydroxypurine
68-94-0

6-hydroxypurine

inosine
58-63-9

inosine

Conditions
ConditionsYield
With recombinant Escherichia coli purine nucleoside phosphorylase at 20℃; pH=7; Kinetics; Reagent/catalyst; Enzymatic reaction;
6-hydroxypurine
68-94-0

6-hydroxypurine

uridine
58-96-8

uridine

inosine
58-63-9

inosine

Conditions
ConditionsYield
With recombinant Escherichia coli purine nucleoside phosphorylase; recombinant Escherichia coli uridine phosphorylase at 20℃; pH=7; Enzymatic reaction;
Allopurinol
68-94-0

Allopurinol

uridine
58-96-8

uridine

inosine
58-63-9

inosine

Conditions
ConditionsYield
With Clostridium perfringens uridine phosphorylase; Aeromonas hydrophila purine nucleosidephosphorylase co-immobilized on glyoxyl-agarose In aq. phosphate buffer at 28℃; under 1034.32 Torr; pH=7.5; Flow reactor; Green chemistry; Enzymatic reaction;
acetic anhydride
108-24-7

acetic anhydride

inosine
58-63-9

inosine

2’,3’,5’-tri-O-acetylinosine
3181-38-2

2’,3’,5’-tri-O-acetylinosine

Conditions
ConditionsYield
With dmap; triethylamine In acetonitrile at 20℃;100%
With pyridine at 0℃; for 16h;
With dmap; triethylamine In acetonitrile for 1h;
inosine
58-63-9

inosine

9-(β-D-arabinofuranosyl)-9H-purin-6(1H)-one
7013-16-3

9-(β-D-arabinofuranosyl)-9H-purin-6(1H)-one

Conditions
ConditionsYield
With uridine phosphorylase; disodium hydrogen arsenate heptahydrate; Escherichia coli purine nucleoside phosphorylase for 48h; Enzymatic reaction;98%
Acetanilid
103-84-4

Acetanilid

inosine
58-63-9

inosine

1,2,3,5-tetraacetylribose
13035-61-5

1,2,3,5-tetraacetylribose

Conditions
ConditionsYield
With aluminum (III) chloride In methanol at 60℃; for 2h; Solvent; Temperature;95%
inosine
58-63-9

inosine

tert-butylchlorodiphenylsilane
58479-61-1

tert-butylchlorodiphenylsilane

9-(2R,3R,4R,5R)-3,4-bis((tert-butyldiphenylsilyl)oxy)-5-((((tert-butyldiphenylsilyl)oxy)methyl)oxolan-2-yl)-9H-purin-6-ol

9-(2R,3R,4R,5R)-3,4-bis((tert-butyldiphenylsilyl)oxy)-5-((((tert-butyldiphenylsilyl)oxy)methyl)oxolan-2-yl)-9H-purin-6-ol

Conditions
ConditionsYield
With zinc(II) chloride; zinc In dichloromethane at 30 - 40℃; for 3h;94.7%
inosine
58-63-9

inosine

C10H10(2)H2N4O5
697807-01-5

C10H10(2)H2N4O5

Conditions
ConditionsYield
With hydrogen; water-d2; palladium 10% on activated carbon at 110 - 140℃; for 48h; Product distribution / selectivity;90%
vinyl acetate
108-05-4

vinyl acetate

inosine
58-63-9

inosine

5'-O-acetylinosine
28526-32-1

5'-O-acetylinosine

Conditions
ConditionsYield
With pyridine; Candida antarctica lipase at 60℃; for 24h;87%
dipentyl ketone
927-49-1

dipentyl ketone

inosine
58-63-9

inosine

9-[(3aR,4R,6R,6aR)-6-(hydroxymethyl)-2,2-dipentyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl]-1,9-dihydro-6Hpurin-6-one

9-[(3aR,4R,6R,6aR)-6-(hydroxymethyl)-2,2-dipentyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl]-1,9-dihydro-6Hpurin-6-one

Conditions
ConditionsYield
With hydrogenchloride; orthoformic acid triethyl ester In 1,4-dioxane; N,N-dimethyl-formamide at 20℃; for 24h;87%
propan-2-one O-butyryl oxime
133360-56-2

propan-2-one O-butyryl oxime

inosine
58-63-9

inosine

Butyric acid (2R,3S,4R,5R)-3,4-dihydroxy-5-(6-hydroxy-purin-9-yl)-tetrahydro-furan-2-ylmethyl ester
145355-70-0

Butyric acid (2R,3S,4R,5R)-3,4-dihydroxy-5-(6-hydroxy-purin-9-yl)-tetrahydro-furan-2-ylmethyl ester

Conditions
ConditionsYield
In tetrahydrofuran at 60℃; for 24h; Candida antarctica lipase (SP435);86%
vinyl acetate
108-05-4

vinyl acetate

inosine
58-63-9

inosine

A

Acetic acid (2R,3S,4R,5R)-4-hydroxy-2-hydroxymethyl-5-(6-hydroxy-purin-9-yl)-tetrahydro-furan-3-yl ester

Acetic acid (2R,3S,4R,5R)-4-hydroxy-2-hydroxymethyl-5-(6-hydroxy-purin-9-yl)-tetrahydro-furan-3-yl ester

B

Acetic acid (2R,3R,4R,5R)-4-hydroxy-5-hydroxymethyl-2-(6-hydroxy-purin-9-yl)-tetrahydro-furan-3-yl ester

Acetic acid (2R,3R,4R,5R)-4-hydroxy-5-hydroxymethyl-2-(6-hydroxy-purin-9-yl)-tetrahydro-furan-3-yl ester

Conditions
ConditionsYield
With Pseudomonas sp. lipase (Lipase PS) In tetrahydrofuran at 30℃; for 96h;A 83%
B n/a
acetone oxime acrylate
145355-61-9

acetone oxime acrylate

inosine
58-63-9

inosine

Acrylic acid (2R,3S,4R,5R)-3,4-dihydroxy-5-(6-hydroxy-purin-9-yl)-tetrahydro-furan-2-ylmethyl ester
145355-75-5

Acrylic acid (2R,3S,4R,5R)-3,4-dihydroxy-5-(6-hydroxy-purin-9-yl)-tetrahydro-furan-2-ylmethyl ester

Conditions
ConditionsYield
In tetrahydrofuran at 60℃; for 15h; Candida antarctica lipase (SP435);80%
thymin
65-71-4

thymin

inosine
58-63-9

inosine

5-Methyluridine
1463-10-1

5-Methyluridine

Conditions
ConditionsYield
With potassium phosphate; xanthine oxidase; purine and pyrimidine nucleoside phosphorylase (PUNP, PYNP) at 40℃; for 11h;76%
With potassium phosphate; xanthine oxidase; PUNP, PYNP at 40℃; for 11h; Equilibrium constant;76%
4-heptanone
123-19-3

4-heptanone

inosine
58-63-9

inosine

9-[(3aR,4R,6R,6aR)-6-(hydroxymethyl)-2,2-dipropyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl]-1,9-dihydro-6Hpurin-6-one

9-[(3aR,4R,6R,6aR)-6-(hydroxymethyl)-2,2-dipropyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl]-1,9-dihydro-6Hpurin-6-one

Conditions
ConditionsYield
With hydrogenchloride; orthoformic acid triethyl ester In 1,4-dioxane; N,N-dimethyl-formamide at 20℃; for 23h;69%
cis-dichloro(DL-ethionine)platinum(II)
21434-62-8, 41475-72-3

cis-dichloro(DL-ethionine)platinum(II)

inosine
58-63-9

inosine

chloro(inosine)(DL-ethionine)platinum(II) chloride

chloro(inosine)(DL-ethionine)platinum(II) chloride

Conditions
ConditionsYield
In water refluxed on a water bath for 3 h; soln. concd., cooled, filtered, filtrate kept in the refrigerator overnight, ppt. filtered off, washed with acetone, dried in vacuo; elem. anal.;68%
inosine
58-63-9

inosine

α-D-ribose-1-phosphate
99790-49-5

α-D-ribose-1-phosphate

Conditions
ConditionsYield
In water at 60℃; for 3h; phosphate buffer pH 7.0; purine nucleoside phosphorylase of Enterobacter aerogenes AJ 11125;55%
With purine nucleoside phosphorylase from aeromonas hydrophila II In aq. phosphate buffer at 20℃; pH=7.5; Reagent/catalyst; Enzymatic reaction;
2-acetoxyethyl acetoxymethyl ether
59278-00-1

2-acetoxyethyl acetoxymethyl ether

inosine
58-63-9

inosine

9-((2-acetoxyethoxy)methyl)-hypoxanthine
150581-50-3

9-((2-acetoxyethoxy)methyl)-hypoxanthine

Conditions
ConditionsYield
With p-toluenesulfonic acid monohydrate; acetic anhydride In acetonitrile47%
inosine
58-63-9

inosine

prenyl bromide
870-63-3

prenyl bromide

6-(3-methyl-2-butenyloxy)-9-(β-D-ribofuranosyl)purine
1237496-78-4

6-(3-methyl-2-butenyloxy)-9-(β-D-ribofuranosyl)purine

Conditions
ConditionsYield
With barium carbonate In N,N-dimethyl-formamide at 20℃; for 24h; Darkness;46%
With barium carbonate In N,N-dimethyl-formamide at 20℃; for 24h;
inosine
58-63-9

inosine

9-(2-O-Triflyl-β-L-ribofuranosyl)hypoxanthine
339091-09-7

9-(2-O-Triflyl-β-L-ribofuranosyl)hypoxanthine

Conditions
ConditionsYield
Stage #1: inosine With di(n-butyl)tin oxide In methanol Heating / reflux;
Stage #2: With trifluoromethane sulfonyl chloride In N,N-dimethyl-formamide at 20℃; for 1h;
37%
inosine
58-63-9

inosine

LACTOSE
5965-66-2

LACTOSE

C16H22N4O10

C16H22N4O10

Conditions
ConditionsYield
With β-galactosidase from Bacillus megaterium YZ08 In dimethyl sulfoxide at 35℃; Solvent; Enzymatic reaction; regioselective reaction;22.4%
1,2,4-triazole-3-carboxamide
3641-08-5

1,2,4-triazole-3-carboxamide

inosine
58-63-9

inosine

ribavirin
36791-04-5

ribavirin

Conditions
ConditionsYield
In water at 60℃; Product distribution; catalyzation by purine nucleoside phosphorylase of Brevibacterium acetylicum ATCC 954, potassium phosphate buffer pH 7.0; reaction time vs. concentrations; with guanosine;
at 60℃; catalyzation by purine nucleoside phosphorylase of Brevibacterium acetylicum ATCC 954, potassium phosphate buffered at pH 7.0; Yield given;
inosine
58-63-9

inosine

A

(2R,4aR,6R,7R,7aS)-7-Hydroxy-6-(6-hydroxy-purin-9-yl)-2-thioxo-tetrahydro-2λ5-furo[3,2-d][1,3,2]dioxaphosphinin-2-ol anion

(2R,4aR,6R,7R,7aS)-7-Hydroxy-6-(6-hydroxy-purin-9-yl)-2-thioxo-tetrahydro-2λ5-furo[3,2-d][1,3,2]dioxaphosphinin-2-ol anion

B

(2S,4aR,6R,7R,7aS)-7-Hydroxy-6-(6-hydroxy-purin-9-yl)-2-thioxo-tetrahydro-2λ5-furo[3,2-d][1,3,2]dioxaphosphinin-2-ol anion

(2S,4aR,6R,7R,7aS)-7-Hydroxy-6-(6-hydroxy-purin-9-yl)-2-thioxo-tetrahydro-2λ5-furo[3,2-d][1,3,2]dioxaphosphinin-2-ol anion

Conditions
ConditionsYield
With potassium hydroxide; trichlorophosphate 1.) trialkyl phosphate, r.t., 1.5 h; 2.) 60 percent CH3CN, 80 deg C; Multistep reaction;
inosine
58-63-9

inosine

A

inosine-5'-aldehyde

inosine-5'-aldehyde

B

inosine-5'-carboxylic acid
15475-13-5

inosine-5'-carboxylic acid

Conditions
ConditionsYield
With oxygen; nucleoside oxidase In water at 25℃; Product distribution; enzyme activity with further nucleoside bases also tested;
benzoyl chloride
98-88-4

benzoyl chloride

inosine
58-63-9

inosine

2',3',5'-tri-O-benzoylinosine
6741-88-4

2',3',5'-tri-O-benzoylinosine

Conditions
ConditionsYield
With pyridine at 27℃; for 24h; Yield given;
inosine
58-63-9

inosine

9-(2,3-Anhydro-β-D-ribofuranosyl)hypoxanthine
31766-13-9

9-(2,3-Anhydro-β-D-ribofuranosyl)hypoxanthine

Conditions
ConditionsYield
With Dowex 1 x 2 (OH(-)); acetoxyisobutyryl bromide 1.) MeCN, 19-22 deg C, 3 h, 2.) MeOH, 1 h; Yield given. Multistep reaction;
inosine
58-63-9

inosine

9-(2,3-Dideoxy-β-D-glycero-pent-2-enofuranosyl)hypoxanthine
42867-68-5

9-(2,3-Dideoxy-β-D-glycero-pent-2-enofuranosyl)hypoxanthine

Conditions
ConditionsYield
Yield given. Multistep reaction;
inosine
58-63-9

inosine

A

Allopurinol
68-94-0

Allopurinol

B

α-D-ribofuranosyl-1-phosphate
18646-11-2

α-D-ribofuranosyl-1-phosphate

Conditions
ConditionsYield
With E. coli purine nucleoside phosphorylase Enzyme kinetics; Substitution;
With Phosphate; Cellulomonas sp. purine nucleoside phosphorylase Enzyme kinetics; phosphorolysis;
divinyl adipate
4074-90-2

divinyl adipate

inosine
58-63-9

inosine

Hexanedioic acid (2R,3S,4R,5R)-3,4-dihydroxy-5-(6-hydroxy-purin-9-yl)-tetrahydro-furan-2-ylmethyl ester vinyl ester

Hexanedioic acid (2R,3S,4R,5R)-3,4-dihydroxy-5-(6-hydroxy-purin-9-yl)-tetrahydro-furan-2-ylmethyl ester vinyl ester

Conditions
ConditionsYield
With [bmim]BF4; Candida antarctica lipase acrylic resin In acetone at 50℃;88 % Chromat.

58-63-9Relevant articles and documents

Enzymatic synthesis of novel purine nucleosides bearing a chiral benzoxazine fragment

Eletskaya, Barbara Z.,Gruzdev, Dmitry A.,Krasnov, Victor P.,Levit, Galina L.,Kostromina, Maria A.,Paramonov, Alexander S.,Kayushin, Alexei L.,Muzyka, Inessa S.,Muravyova, Tatyana I.,Esipov, Roman S.,Andronova, Valeria L.,Galegov, Georgiy A.,Charushin, Valery N.,Miroshnikov, Anatoly I.,Konstantinova, Irina D.

, p. 605 - 616 (2019)

A series of ribo- and deoxyribonucleosides bearing 2-aminopurine as a nucleobase with 7,8-difluoro- 3,4-dihydro-3-methyl-2H-[1,4]benzoxazine (conjugated directly or through an aminohexanoyl spacer) was synthesized using an enzymatic transglycosylation reaction. Nucleosides 3-6 were resistant to deamination under action of adenosine deaminase (ADA) Escherichia coli and ADA from calf intestine. The antiviral activity of the modified nucleosides was evaluated against herpes simplex virus type 1 (HSV-1, strain L2). It has been shown that at sub-toxic concentrations, nucleoside (S)-4-[2-amino-9-(β-D-ribofuranosyl)-purin-6-yl]-7,8-difluoro-3,4-dihydro-3-methyl-2H-[1,4]benzoxazine exhibit significant antiviral activity (SI?>?32) on the model of HSV-1 in vitro, including an acyclovir-resistant virus strain (HSV-1, strain L2/R).

3'-β-ethynyl and 2'-deoxy-3'-β-ethynyl adenosines: First 3'-β- branched-adenosines substrates of adenosine deaminase

Tritsch, Denis,Jung, Pierre M. J.,Burger, Alain,Biellmann, Jean-Francois

, p. 139 - 141 (2000)

The 3'-C-branched-adenosine and 2'-deoxyadenosine analogues 1-7 were tested as substrate of adenosine deaminase. The 9-(3'-C-ethynyl-β-D-ribo- pentofuranosyl)adenine 1 and its 2'-deoxy analogue 7 were deaminated by the enzyme while the vinyl and ethyl derivatives 2 and 3 were not. The 9-(3'-C- branched-β-D-xylo-pentofuranosyl)adenines 4-6 were deaminated by the deaminase.

Nucleolipids of Canonical Purine ?- D -Ribo-Nucleosides: Synthesis and Cytostatic/Cytotoxic Activities Toward Human and Rat Glioblastoma Cells

Knies, Christine,Hammerbacher, Katharina,Bonaterra, Gabriel A.,Kinscherf, Ralf,Rosemeyer, Helmut

, p. 129 - 141 (2016)

We report on the synthesis of two series of canonical purine ?-d-ribonucleoside nucleolipids derived from inosine and adenosine, which have been characterized by elemental analyses, electrospray ionization mass spectrometry (ESI MS) as well as by 1H and 13CNMR, and pH-dependent UV/Vis spectroscopy. A selection of the novel nucleolipids with different lipophilic moieties were first tested on their cytotoxic effect toward human macrophages. Compounds without a significant inhibitory effect on the viability of the macrophages were tested on their cytostatic/cytotoxic effect toward human astrocytoma/oligodendroglioma GOS-3 cells as well as against the rat malignant neuroectodermal BT4Ca cell line. In order to additionally investigate the potential molecular mechanisms involved in the cytotoxic effects of the derivatives on GOS-3 or BT4Ca cells, we evaluated the induction of apoptosis and observed the particular activity of the nucleolipid ethyl 3-{4-hydroxymethyl-2-methyl-6-[6-oxo-1-(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-1,6-dihydro-purin-9-yl]-tetrahydro-furo[3,4-d][1,3]dioxol-2-yl}propionate (8 c) toward both human and rat glioblastoma cell lines invitro. Nucleolipids combat cancer: We report the synthesis of two nucleolipid derivatives from inosine and adenosine with different lipophilic moieties. These have no cytotoxic effect on human macrophages based on invitro side-effect tests but have antiproliferative properties against malignant glioblastoma cell lines.

Determination of adenosine deaminase activity in dried blood spots by a nonradiochemical assay using reversed-phase high-performance liquid chromatography

Van Kuilenburg,Zoetekouw,Meijer,Kuijpers

, p. 461 - 465 (2010)

Adenosine deaminase (ADA) deficiency is a rare metabolic disease causing severe combined immunodeficiency (SCID). An assay to determine ADA activity in dried blood spots was developed using reversed-phase HPLC. The assay was linear with reaction times up to at least 4 hours, and protein concentrations up to at least 2.2 mg/ml. The intra-assay CV and the inter-assay CV for the complete assay was 3.5 and 8.4%, respectively. The ADA activity in a control blood spot, stored at 4°C, remained stable for at least one year. Only a slightly decreased ADA activity (35 ± 13 nmol/mg/h, n = 4) was observed in heterozygotes for a c.704G > A mutation in the ADA gene when compared to that observed in controls (41 ± 13 nmol/mg/h, n = 108). In addition, increased ADA activity as found in a rare form of congenital anemia can be assessed, as observed in a bloodspot from a patient diagnosed with Diamond Blackfan anemia (ADA activity 150 nmol/mg/h). Copyright

Simultaneous detection of ATP and GTP by covalently linked fluorescent ribonucleopeptide sensors

Nakano, Shun,Fukuda, Masatora,Tamura, Tomoki,Sakaguchi, Reiko,Nakata, Eiji,Morii, Takashi

, p. 3465 - 3473 (2013)

A noncovalent RNA complex embedding an aptamer function and a fluorophore-labeled peptide affords a fluorescent ribonucleopeptide (RNP) framework for constructing fluorescent sensors. By taking an advantage of the noncovalent properties of the RNP complex, the ligand-binding and fluorescence characteristics of the fluorescent RNP can be independently tuned by taking advantage of the nature of the RNA and peptide subunits, respectively. Fluorescent sensors tailored for given measurement conditions, such as a detection wavelength and a detection concentration range for a ligand of interest can be easily identified by screening of fluorescent RNP libraries. The noncovalent configuration of a RNP becomes a disadvantage when the sensor is to be utilized at very low concentrations or when multiple sensors are applied to the same solution. Here, we report a strategy to convert a fluorescent RNP sensor in the noncovalent configuration into a covalently linked stable fluorescent RNP sensor. This covalently linked fluorescent RNP sensor enabled ligand detection at a low sensor concentration, even in cell extracts. Furthermore, application of both ATP and GTP sensors enabled simultaneous detection of ATP and GTP by monitoring each wavelength corresponding to the respective sensor. Importantly, when a fluorescein-modified ATP sensor and a pyrene-modified GTP sensor were co-incubated in the same solution, the ATP sensor responded at 535 nm only to changes in the concentration of ATP, whereas the GTP sensor detected GTP at 390 nm without any effect on the ATP sensor. Finally, simultaneous monitoring by these sensors enabled real-time measurement of adenosine deaminase enzyme reactions.

Enzymatic displacement of oxygen and sulfur from purines.

Wolfenden,Kirsch

, p. 6849 - 6850 (1968)

-

Prebiotic Photochemical Coproduction of Purine Ribo- And Deoxyribonucleosides

Xu, Jianfeng,Green, Nicholas J.,Russell, David A.,Liu, Ziwei,Sutherland, John D.

supporting information, p. 14482 - 14486 (2021/09/18)

The hypothesis that life on Earth may have started with a heterogeneous nucleic acid genetic system including both RNA and DNA has attracted broad interest. The recent finding that two RNA subunits (cytidine, C, and uridine, U) and two DNA subunits (deoxyadenosine, dA, and deoxyinosine, dI) can be coproduced in the same reaction network, compatible with a consistent geological scenario, supports this theory. However, a prebiotically plausible synthesis of the missing units (purine ribonucleosides and pyrimidine deoxyribonucleosides) in a unified reaction network remains elusive. Herein, we disclose a strictly stereoselective and furanosyl-selective synthesis of purine ribonucleosides (adenosine, A, and inosine, I) and purine deoxynucleosides (dA and dI), alongside one another, via a key photochemical reaction of thioanhydroadenosine with sulfite in alkaline solution (pH 8-10). Mechanistic studies suggest an unexpected recombination of sulfite and nucleoside alkyl radicals underpins the formation of the ribo C2′-O bond. The coproduction of A, I, dA, and dI from a common intermediate, and under conditions likely to have prevailed in at least some primordial locales, is suggestive of the potential coexistence of RNA and DNA building blocks at the dawn of life.

An enzymatic flow-based preparative route to vidarabine

Annunziata, Francesca,Bavaro, Teodora,Calleri, Enrica,Conti, Paola,Pinto, Andrea,Previtali, Clelia,Rinaldi, Francesca,Speranza, Giovanna,Tamborini, Lucia,Terreni, Marco,Ubiali, Daniela

, (2020/03/23)

The bi-enzymatic synthesis of the antiviral drug vidarabine (arabinosyladenine, ara-A), catalyzed by uridine phosphorylase from Clostridium perfringens (CpUP) and a purine nucleoside phosphorylase fromAeromonas hydrophila (AhPNP), was re-designed under continuous-flow conditions. Glyoxyl-agarose and EziGTM1 (Opal) were used as immobilization carriers for carrying out this preparative biotransformation. Upon setting-up reaction parameters (substrate concentration and molar ratio, temperature, pressure, residence time), 1 g of vidarabine was obtained in 55% isolated yield and >99% purity by simply running the flow reactor for 1 week and then collecting (by filtration) the nucleoside precipitated out of the exiting flow. Taking into account the substrate specificity of CpUP and AhPNP, the results obtained pave the way to the use of the CpUP/AhPNP-based bioreactor for the preparation of other purine nucleosides.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 58-63-9